$16.70
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating
Overview
52-week range
$8.60
$18
88% of range
Avg surprise (last 3)
+2.6%
Avg reaction (last 2)
+1.2%
100% positive
Latest IV / EM
196%
EM ±32.8% · $18 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.40 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.39 | $-0.55 | +29.1% | +37.1% | +1.7% | earnings |
| Tue Aug 5, 2025 | Jun/2025 | $-0.62 | $-0.56 | -10.7% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.62 | $-0.56 | -10.7% | — | +0.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.40 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.39 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.69 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.84 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-17M | $-17M | — | $-15M | $-18M | $-18M | — | $-13M |
| Net income | $-15M | $-14M | — | $-13M | $-16M | $-16M | — | $-10M |
| EPS (diluted) | $-0.40 | $-0.39 | — | — | $-0.62 | $-0.62 | — | $-0.40 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15M | $20M | $76M | $43M | $21M | $22M | $22M | $41M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $243M | $253M | $268M | $185M | $177M | $192M | $206M | $215M |
| Total assets | $250M | $261M | $277M | $191M | $183M | $198M | $213M | $216M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $11M | $16M | $10M | $11M | $13M | $15M | $6M |
| Total equity | $240M | $250M | $261M | $180M | $171M | $185M | $198M | $210M |